Lowering cholesterol, you can lower your risk of Alzheimer’s disease
Early treatment of traditional risk factors for heart disease, such as hypertension, high cholesterol, diabetes, may also prevent memory loss and cognitive problems that lead to Alzheimer’s disease. While proper nutrition for most people is variable, the cholesterol-lowering drugs and medications for hypertension, such as beta-blockers, are far from proven way to prevent Alzheimer’s disease.
And yet, while they improve the health of blood vessels and can be a practical way to reduce the risk of disease. The study, which was conducted in China and published in the journal Neurology, is emphasizing the importance of the middle years of the risk factors of Alzheimer’s disease, which, in contrast to the age and genetics, can be treated.
Researchers at the hospital Daping, for 5 years observed 638 men and women aged 55 years. All study participants had problems with memory and mental function that are visible, but not serious enough for medical intervention. This initial condition known as progressive cognitive impairment, according to the study progresses to Alzheimer’s disease in approximately 10% to 15% each year.
Forty-five percent of the participants developed dementia compatible with Alzheimer’s disease. Those who had high cholesterol, hypertension, diabetes, or other heart-related risk factors were twice more likely to make Alzheimer’s disease compared to people without these risk factors.
Treatment, be that as it may significantly reduce the risk. Compared to those participants who did not receive it, participants who engaged in treatment, do clean the liver and other steps to improve their heart health by 39% reduces the potential for acquiring Alzheimer’s disease. Even those who are treated only some of the risk factors, a 26% reduced risk of disease.
Researchers have long known about the apparent connection between the cardiovascular system and Alzheimer’s disease, but this study – the first, which shows that the treatment of progressive cognitive deterioration can be positive.
It is not clear why the treatment-related heart risk factors could reduce the risk of Alzheimer’s disease, but high blood pressure and high cholesterol can affect the accumulation of protein in malignant brain and is responsible for the state of memory in humans.
While the results are encouraging, the study can not prove that the treatment itself directly reduces the risk of Alzheimer’s disease.
Random follow-up, which are considered the gold standard of medical research will be needed to confirm the results. A study should be conducted in other countries. True, there is a view that the results of these observations and studies are likely to be soo well as in China, as the western population tends to have a higher incidence of metabolic disorders such as obesity and high cholesterol.